Growth hormone (GH) has growth and metabolic functions. It stimulates the production of insulinlike growth factor-I (IGF-I) in the liver. IGF-I mediates the growth promoting activities of GH. Knockout mouse models with disruption of GH receptor, IGF-I or IGF-I receptor, highlight the importance of GH and IGF-I in maintaining bone metabolism and bone mineral density (BMD) [1][2][3]. In human, lack of GH is associated with reduced BMD and osteoporosis is observed in patients with severe adult GH deficiency [4, 5] . Furthermore, replacement therapy using recombinant human GH (rhGH) increases BMD in such patients [6, 7] . These results indicate that GH and IGF-I play an important role in maintaining bone metabolism and BMD in adulthood, in addition to stimulating longitudinal bone growth in childhood. However, information
on the effect of GH excess on bone metabolism and BMD is incomplete and requires further analysis.
Acromegaly is mainly seen in patients with GH-secreting pituitary tumors. The high levels of GH and IGF-I result in the characteristic signs and symptoms of acromegaly. With regard to musculoskeletal tissues in acromegaly, the effects of excess GH and IGF-I on BMD are conflicting. Some studies have described increased BMD in patients with active acromegaly [8] [9] [10] , though aging, sex and hypogonadism in such patients correlate with decreased BMD [8, 11] . GH excess causes an increase in bone turnover markers, such as bone formation and resorption markers [12] . Previous studies reported that treatment with GH receptor antagonist in acromegaly resulted in reduction of bone turnover [13, 14] , but there is no information on the relationship between changes in bone turnover and BMD in patients with acromegaly.
To our knowledge, there are no prospective studies that have examined bone metabolism and BMD before and after transsphenoidal surgery (TSS) in acromegalic patients. In such patients, BMD should decrease after tion marker (urinary type I collagen cross-linked N-telopeptide: urinary NTx), BMD and body composition were measured before, at 3 and 12 months after surgery. Fasting blood and non-first void urinary samples were collected in the morning. BAP was measured by chemiluminescent enzyme immunoassay: CLEIA (Access Ostase assay, Beckman Coulter, Inc. Tokyo, Japan) (reference range: males 3.7-20.9 µg/L, females 2.9-14.5 µg/L). Urinary NTx was measured by enzyme-linked immunosorbent assay: ELISA (Osteomark, Alere, Inc. Tokyo) (reference range: 9.3-54.3 nmol bone collagen equivalent/mmol creatinine (nmolBCE/mmol • CRE)).
BMD and body composition were evaluated by dualenergy X-ray absorptiometry (DXA) using a Discovery A (Hologic, Bedford, MA). BMD was measured at the second to fourth lumbar vertebrae, femoral neck and the 33% radius of the other side of the dominant hand, and expressed in absolute values (g/cm 2 ) and in standard deviations from peak bone mass (T-score) and from expected BMD for age-matched population (Z-score).
Statistical analysis
The measured variables are expressed as median with interquartile range (1st and 3rd quartiles). The Z-score of acromegalic patients before TSS was analyzed using Wilcoxon signed-rank test and Wilcoxon rank sum test. The time course data were analyzed using generalized estimating equations (GEE). Two-sided P<0.05 denoted the presence of a statistically significant difference. Subject characteristics data for two groups was compared by median of Mann-Whitney U test for continuous variables and by Fisher exact test for categorical variables. All statistical analyses were performed using SAS 9.3 for Window (SAS Institute, Cary, NC).
results
Fifteen patients with acromegaly who underwent TSS were considered to have reached remission based on suppression of serum GH levels below 1 μg/L after OGTT. TSS failed to completely control GH hypersecretion in the remaining 7 patients. Among the latter group, 5 patients were treated with long-acting somatostatin analog, while the other 2 patients received long-acting somatostatin analog and dopamine agonists after TSS. Serum IGF-I levels were controlled in all patients within the age-and sex-adjusted reference range for Japanese population [15] . Twelve patients (4 TSS if excess GH increases BMD, with resultant need to treat osteoporosis in such patients. To test the above hypothesis, we need to check changes in both bone metabolism and BMD. The purpose of this prospective study was to determine the effect of rapid decline in GH levels on bone metabolism. For this purpose, we measured bone turnover markers and BMD before and after TSS in patients with active acromegaly.
Subjects and methods

Subjects
We Table 1 ). The diagnosis of acromegaly was based on the following criteria: 1) Clinical features (acral enlargement, acromegalic features, macroglossia), 2) lack of suppression of serum GH levels below 1 μg/L after a 75g oral glucose tolerance test (OGTT), with serum IGF-I levels above the upper limit of the normal range, 3) identification of a pituitary mass on magnetic resonance imaging. Hyogonadism in men was diagnosed by low serum testosterone concentrations. In women, the presence of low serum estradiol concentrations and/or abnormalities of the menstrual cycle, such as amenorrhea and menopause, were diagnosed as hypogonadism. None of the patients had history of bone fracture by their interviews, and none used any drug for the treatment of osteoporosis, including anti-osteoporosis drugs, vitamin D or calcium supplementation at the start and during the study.
The study protocol was reviewed and approved by the ethics committee of Osaka University (reference no UMIN000004665) and performed according to the Helsinki declaration. All patients provided signed informed consent before participation in the study.
Methods
All patients with active acromegaly underwent TSS. After TSS, serum GH levels were measured after OGTT. Patients in whom serum GH level did not decrease below 1 μg/L after OGTT were placed on long-acting somatostatin analog and/or dopamine agonists to control GH hypersecretion.
In all patients, GH, IGF-I, bone formation marker (serum bone alkaline phosphatase: BAP), bone resorp-males and 8 females) were diagnosed with hypogonadism before TSS. Any symptom of hypogonadism was not restored during the study period in these patients. The clinical characteristics are summarized in Table 1 . GH and IGF-I levels were significantly decreased at 3 and 12 months after TSS (Table 2) .
Bone turnover
The frequency of abnormal BAP elevation was significantly higher in female patients (100 %) than in male patients (54.6 %) (P = 0.035) although the median BAP levels in female patients were not different from in male patients (male: median BAP 22.2 µg/L, range 19.7 -34.3 µg/L; female: median BAP 23.5 µg/L, range 20.8 -36.6 µg/L, P = 0.629). Urinary NTx levels at baseline were above the respective reference range (median urinary NTx 98.9 nmolBCE/mmol • CRE, range 79.0 -138.4 nmolBCE/mmol • CRE). There was a significant relationship between BAP and urinary NTx (r = Hypogonadal patients (n, %) 12 (55%)
Diabetes or IGT (n, %) 16 (73%)
IGT, impaired glucose tolerance The measured variables are expressed as median values (1st and 3rd quartiles). radius compared with male patients (Fig. 1B) . Male and female patients with hypogonadism tended to have lower Z-scores of the lumbar spine and 33% radius BMD (Fig. 1C, 1D) . GEE showed no decrease in BMD at 3 and 12 months after TSS (Table 2 ). In both male and female patients, no significant change was noted in BMD throughout the study (Fig. 2) , and no difference in percent change in BMD was found after TSS, relative to the value before surgery. Furthermore, the presence of hypogonadism and BMD level at baseline had no influence on the change in BMD during the study (data not shown).
With regard to body composition, body fat percentage was significantly increased at 12 months after TSS although there was not any significant change of body weight and BMI during the study (Table 2) . 0.738, P<0.0001). BAP was significantly lower at 12 months after TSS, but not at 3 months, compared with the baseline (Table 2) . On the other hand, urinary NTx was significantly lower at 3 and 12 months after TSS compared with the baseline value ( Table 2) . These results demonstrated high levels of bone formation and resorption in acromegalic patients before TSS and that both decreased after TSS. Interestingly, the decrease in bone resorption occurred earlier than bone formation after TSS.
Bone mineral density and body composition
At baseline, femoral neck Z-score of BMD was significantly higher than that of age-matched population (Fig. 1A) . The Z-score of BMD in female patients was significantly higher in the femoral neck and 33% Analysis of data of all patients (n=22, A), showed that femoral neck Z-score was significantly higher than age-matched population. BMD was evaluated according to gender (B) and gonadal state (C, D). BMD of female patients was significantly higher in the femoral neck and 33% radius compared with male patients. Female patients with hypogonadism had low BMD of 33% radius compared with eugonadal patients. simultaneously with the change in bone formation marker after a rapid decline in GH levels. Ueland et al. [12] investigated bone metabolism in patients with acromegaly using markers of bone formation (osteocalcin) and resorption (C-terminal telopeptides of type I collagen). They found both markers to be elevated in patients with acromegaly. Parkinson et al. [13] reported that treatment with GH receptor antagonist significantly decreased the levels of markers of bone formation and resorption in acromegalic patients.
Discussion
In our study, treatment of acromegalic patients by TSS significantly decreased both bone resorption and formation markers. Interestingly, urinary NTx, a marker of bone resorption was significantly decreased at 3 and 12 months after TSS, but BAP, as a marker of bone formation was significantly decreased at 12 months after TSS, but not at 3 months. These results demonstrated that the change in bone resorption marker did not occur The BMD of all patients (n=22, A, B, C), male (n=11, D, E, F) and female (n=11, G, H, I) patients were not decreased at 3 and 12 months after TSS. study was small (7 patients) and the study was substudy of a multicenter phase IV trial that examined the effects of switching treatment from long-acting octreotide to pegvisomant [20] . Treatment with pegvisomant increases serum GH levels as well as reduces IGF-I level in acromegalic patients [21] . Treatment with pegvisomant increased bone growth in hypophysectomized (GH-deficient) rats, and the effect thought to be mediated through pegvisomant interaction with prolactin receptor [22] . In addition, Jimenez et al. [19] found that all their patients with acromegaly use calcium and vitamin D supplementations. The high BMD in acromegalic patients could be due to the use of vitamin D supplementation in their study. These results indicate that various treatment modalities for acromegaly could influence the observed changes in BMD and bone turnover markers in acromegalic patients. O'Sullivan et al. reported that fat mass was increased by treatment of acromegaly. They concluded that GH was a regulator of energy metabolism and body composition [23] . We also showed that body fat percentage was significantly increased at 12 months after TSS. This result reflected the decline in GH and IGF-I levels after TSS.
As a limitation, it should be noted that the sample size and the observation period still were not enough. The present study did not evaluate bone quality. Therefore, we could not evaluate this issue in our patients. Further long-term prospective studies in large number of patients are needed to confirm our findings and to evaluate bone quality to determine the risk of bone fracture in acromegalic patients.
In conclusion, the present study demonstrated that a rapid reduction in GH levels after TSS does not affect BMD up to 12 months after surgery despite the decrease in both bone formation and resorption markers.
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Replacement therapy with rhGH for adult GH deficiency results in an increase in bone turnover, which is defined by changes in biochemical markers of bone resorption and formation. The effect of rhGH on bone is biphasic: maximal effect on bone resorption after 3 months and maximal effect on bone formation after 6 months [6, 16] . Our results showed a positive relationship between markers of bone formation and resorption in patients with active acromegaly (r = 0.738, P<0.0001). This finding was similar to that described in a previous study [12] . The positive relation with bone turnover markers suggests synchronization of bone turnover. Such synchronization is called "coupling phenomenon". Coupling phenomenon has been discussed in studies of adult GH deficiency [17, 18] , and it is defined as bone remodeling initiated by osteoclastic resorption followed by osteoblastic bone formation. Our results showed that the change in bone resorption occurred earlier than that in bone formation regardless of the increase or decrease in GH levels.
Previous reports showed that Z-scores of BMD were significantly higher in acromegalic patients compared to control subjects [8, 10] , and that BMD in female patients with active acromegaly was higher than in their male counterparts [8] . In our study, the frequency of abnormal BAP elevation was significantly higher in female patients (100 %) than in male patients (54.6 %) (P = 0.035). These results indicated that there is an increase in bone formation in female patients than in male patients and might explain that the Z-score of BMD in female patients was significantly higher in the femoral neck and 33% radius compared with male patients.
In this study, we prospectively evaluated BMD before and after TSS in patients with active acromegaly. Our study showed that the rapid decline in GH levels was not directly associated with a decrease in BMD at 3 and 12 months after TSS. Jimenez et al. [19] reported that treatment of acromegalic patients with pegvisomant, a GH receptor antagonist, increased BMD of the lumbar spine at 8 months and that of hip at 18 months. However, the number of subjects in their 
